Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study

Journal of Clinical Oncology

Volumn 14, Issue 12, 1996, Pages 3056-3061

  Creemers, G J ^a   Bolis, G ^a   Gore, M ^a   Scarfone, G ^a   Lacave, A J ^a   Guastalla, J P ^a   Despax, R ^a   Favalli, G ^a   Kreinberg, R ^a   Van Belle, S ^a   Hudson, I ^a   Verweij, J ^a   Ten Bokkel Huinink, W W ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GYRASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 10544229791     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.12.3056     Document Type: Article

References (33)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1991. Cancer J Clin 41:19-52, 1991
2. Ozols RF, Rubin SC, Dembo AJ, et al: Epithelial ovarian cancer, in Hoskins WJ, Perez CA, Young RC (eds): Principles of Gynaecologic Oncology. Philadelphia, PA, Lippincott, 1992, pp 731-781
3. Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute treatment referral center 9103. J Clin Oncol 11:2405-2410, 1993
4. Einzig AL, Wiernik PH, Sasloff J, et al: Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992
5. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
6. Thigpen T, Blessing J, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynaecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
7. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
9. Aapro M, Pujade-Lauraine E, Lhomme C, et al: EORTC Clinical Screening Group: Phase II study of Taxotere in ovarian cancer. Ann Oncol 5:202, 1994 (suppl 5)
10. Piccart MJ, Gore M, ten Bokkel Huinink W, et al: Docetaxel: An active new drug for treatment of advanced ovarian cancer. J Natl Cancer Inst 87:676-681, 1995
11. Kavanagh JJ, Kudelka AP, Freedman RS, et al: A phase II trial of Taxotere in ovarian cancer patients refractory to cisplatin/carboplatin therapy. Proc Am Soc Clin Oncol 12:259, 1993 (abstr)
12. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
13. Creemers GJ, Lund B, Verweij J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994
14. Patresi G, Tortoreto M, Giaridini R, et al: Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br J Cancer 71:525-528, 1995
15. Kudelka A, Edwards C, Freedman R, et al: A phase II study of topotecan administered intravenously as a 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma. Eur J Cancer 29A:S132, 1993 (suppl 6)
16. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
17. Blackledge G, Lawton F, Redman C, et al: Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials. Br J Cancer 59:650-653, 1989
18. Seltzer V, Vogt S, Kaplan B: Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminodichloroplatinum in patients previously responding to this agent. Gynecol Oncol 21:167-176, 1985
19. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979
20. National Cancer Institute: Guidelines for Reporting Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
21. Amstrong D, Rowinsky E, Donehower R, et al: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:275, 1995 (abstr)
22. Hansen HH, Eisenhauer EA, Hansen M, et al: New cytostatic drugs in ovarian cancer. Ann Oncol 4:S63-S70, 1993 (suppl 4)
23. Padzur R, Kudelka AP, Kavanagh JJ, et al: The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19:351-386, 1993
24. Francis P, Schneider J, Hann L et al: Phase II trial of docetaxel in patients with platinum refractory advanced ovarian cancer. J Clin Oncol 11:2301-2308, 1994
25. Verweij J, Clavel M, Chevalier B: Paclitaxel (Taxol) and docetaxel (Taxotere): Not just simply two of a kind. Ann Oncol 5:495-505, 1994
26. Houghton PJ, Chesire PJ, Hallman JC, et al: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4)[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylamino-methyl-10-camptothecin. Cancer Res 53:2823-2829, 1993
27. Bums HA, Hanauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84:1816-1820, 1992
28. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994
29. Creemers GJ, Schellens JHM, Beynen JH, et al: Bioavailability of oral topotecan, a new topoisomerase I inhibitor. Proc Am Soc Clin Oncol 13:132, 1994 (abstr)
30. Katz EJ, Vick JS, Kling KM, et al: Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer 26:724-727, 1990
31. Drewinko B, Green C, Loo TL, et al: Combination chemotherapy in vitro with cis-dichlorodiammine platinum. Cancer Treat Rep 60:1619-1625, 1976
32. Rowinsky E, Grochow L, Ettinger D, et al: Sequence-dependent effects of topotecan (T) and cisplatin (C) in a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 13:142, 1994 (abstr)
33. Saltz L, Kanowitz J, Schwartz G, et al: Phase I trial of cisplatin (DDP) plus topotecan (T) on a daily ×5 schedule in patients with advanced solid tumors. Proc Am Soc Clin Oncol 14:475, 1995 (abstr)